SBRT combined with Tislelizumab followed by Tislelizumab
2024-Ethical Review -01
Phase 2 small_molecule active
Quick answer
SBRT combined with Tislelizumab followed by Tislelizumab for NSCLC is a Phase 2 program (small_molecule) at Zibo Municipal Hospital with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Zibo Municipal Hospital
- Indication
- NSCLC
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active